PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) has announced financial results for the first quarter ended March 31, 2025, alongside updates on its clinical pipeline and leadership. The company continues to advance its portfolio of T cell-engaging therapies targeting solid tumors.
According to CEO Martin Lehr, Context now has two product candidates in Phase 1 clinical trials. CTIM-76, a Claudin 6 x CD3 bispecific antibody, is being developed for gynecologic and testicular cancers, with initial data expected in the first half of 2026. CT-95, a mesothelin x CD3 bispecific antibody targeting advanced solid tumors such as ovarian and pancreatic cancers, is also in trials, with data anticipated by mid-2026. Additionally, the company plans to file an IND for CT-202, a Nectin-4 x CD3 bispecific antibody, in mid-2026.
Key first-quarter developments include dosing the first patients in Phase 1 trials for both CTIM-76 and CT-95 and presenting preclinical data on CT-95 at the AACR Annual Meeting 2025. Leadership updates include the appointment of Dr. Karen Smith as Interim Chief Medical Officer and Andy Pasternak as Chairman of the Board.
Financially, Context ended the quarter with $89.4 million in cash and cash equivalents, supporting operations through 2027. R&D expenses rose to $3.5 million, reflecting increased investment in CT-95 and CT-202 programs, while general and administrative expenses also saw a slight rise to $2.1 million. Overall, the company reported a net loss of $4.6 million, compared to a $3.7 million loss in Q1 2024.
With a solid financial foundation and an expanding clinical pipeline, Context remains focused on pioneering innovative therapies for complex solid tumor challenges.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.